The Type 1 Diabetes Market is estimated at US$18.5 billion in 2026 and is projected to grow at a CAGR of 7.1% to reach US$32 billion by 2034.
Its value chain includes insulin manufacturers, device makers, glucose sensor companies, pharmacies, hospitals, endocrinology clinics, payers, and patient communities. Core applications include insulin therapy, continuous glucose monitoring, pump based delivery, pediatric diabetes care, digital disease management, and hospital endocrinology support.
This product will be delivered within 1-3 business days.
Market Overview
The Type 1 Diabetes Market covers therapeutic products, monitoring technologies, insulin delivery systems, and supportive care solutions used to manage autoimmune insulin dependent diabetes.Its value chain includes insulin manufacturers, device makers, glucose sensor companies, pharmacies, hospitals, endocrinology clinics, payers, and patient communities. Core applications include insulin therapy, continuous glucose monitoring, pump based delivery, pediatric diabetes care, digital disease management, and hospital endocrinology support.
Key Companies Analysed
- Novo Nordisk
- Eli Lilly
- Sanofi
- Medtronic
- Dexcom
- Abbott
- Insulet
- Tandem Diabetes Care
- Roche
- Ypsomed
- Senseonics
- Beta Bionics
- Bigfoot Biomedical
- Ascensia Diabetes Care
- Becton Dickinson
- MannKind
- Vertex Pharmaceuticals
- Sernova
- Oramed
- AstraZeneca
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Type 1 Diabetes Market Overview
3. Type 1 Diabetes Market Dynamics
4. Type 1 Diabetes Market Strategic Analysis
5. Global Type 1 Diabetes Market Size, Share and Forecast, 2025-2034
6. North America Type 1 Diabetes Market Outlook to 2034
7. Europe Type 1 Diabetes Market Outlook to 2034
8. Asia-Pacific Type 1 Diabetes Market Outlook to 2034
9. Middle East and Africa Type 1 Diabetes Market Outlook to 2034
10. South and Central America Type 1 Diabetes Market Outlook to 2034
11. Type 1 Diabetes Market Competitive Landscape
12. Appendix
Companies Mentioned
- Novo Nordisk
- Eli Lilly
- Sanofi
- Medtronic
- Dexcom
- Abbott
- Insulet
- Tandem Diabetes Care
- Roche
- Ypsomed
- Senseonics
- Beta Bionics
- Bigfoot Biomedical
- Ascensia Diabetes Care
- Becton Dickinson
- MannKind
- Vertex Pharmaceuticals
- Sernova
- Oramed
- AstraZeneca
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 18.5 Billion |
| Forecasted Market Value ( USD | $ 32 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
